**Core tip:** The question of whether serum uric acid has a pathogenic role in the onset and progression of chronic kidney disease (CKD) remains unanswered. Hyperuricemia and gout is common in CKD, and treatment adherence in gout patients is suboptimal and therefore a therapeutic challenge. Our population-based study assessed the impact of gout disease control on the risk of end stage renal disease (ESRD). Our study suggest that adherence to allopurinol of ≥ 80% as a proxy for gout control is associated with a significant, 65% reduction in the risk of ESRD onset.

INTRODUCTION
============

Gout is a chronic disease and one of the most common inflammatory arthritis conditions among adults. Gout is caused primarily by inefficient renal excretion of uric acid, resulting in increased serum uric acid (sUA) levels (*i.e*., hyperuricemia), and ultimately, deposition of monosodium urate crystals within joints, connective tissue, kidneys, and other organs. The accumulation of crystal deposits lead to acute, painful inflammatory arthritis (*i.e*., flares) and tophi; if not appropriately treated, gout can cause permanent joint destruction, bone erosion, and kidney damage\[[@B1]\]. The prevalence estimates of gout from the 2007 to 2008 United States National Health and Nutrition Examination Survey are 5.6% among men and 2.0% among women\[[@B2]\].

The pathogenesis of gout is well established, and the role of sUA for acute and chronic conditions of gout is linked to the deposition of monosodium urate crystals. Reducing sUA levels prevents further crystal deposition and allows dissolution of existing deposits, effectively curing the disease. The American College of Rheumatology\[[@B3]\] and European League Against Rheumatism\[[@B4]\] have published guidelines for the use of urate-lowering therapies for gout management. Targeting sUA is important in the management of gout because high levels are linked to up to a 3-times risk of an acute gout flare\[[@B5]\] and a higher annual frequency of flares\[[@B6]\]. Moreover, studies report continued poor outcomes in gout patients\[[@B7]\], including recurrent flares, functional incapacity, and risk of additional joint damage, as well as the potential for renal and cardiovascular complications\[[@B8]\]. The potential relationship of elevated sUA and all-cause mortality has also been suggested by several population-based\[[@B9],[@B10]\] cohort studies. Recent estimates have shown that overall aggregate annual costs for the medical care of gout patients exceeded \$20 billion in the United States alone, with provisional estimates of annual direct and indirect costs of gout patient care totaling over \$6 billion\[[@B11]\].

In a recent meta-analysis on adherence to allopurinol, it was clear that allopurinol adherence was suboptimal and therefore a therapeutic challenge in gout\[[@B12]\]. Among the systematic reviews provided in the meta-analysis, 1 study evaluated adherence rates among patients with 7 different medical conditions, including hypertension (72.3%), hypothyroidism (68.4%), diabetes mellitus (65.4%), seizure disorders (60.8%), hypercholesterolemia (54.6%), osteoporosis (51.2%), and gout (36.8%), suggesting that adherence was worst in gout\[[@B13]\].

These results highlight the need for more research on the impact of allopurinol non-adherence on major clinical outcomes, such as kidney disease. In fact, hyperuricemia is common in chronic kidney disease (CKD), and it is thought to develop secondary to a decrease in glomerular filtration rate or hyperinsulinemia in the metabolic syndrome\[[@B14]\]. It is generally accepted that hyperuricemia is prevalent among patients with several risk factors for cardiovascular disease (CVD)\[[@B15]\], and elevated sUA levels have been found to predict the risk of developing CVD or CKD in the general population\[[@B16],[@B17]\]. However, the question of whether sUA has a pathogenic role in the onset and progression of CKD remains unanswered.

Several observational studies have investigated whether an elevated sUA level is an independent risk factor for the development and progression of CKD, but the results were inconclusive and conflicting\[[@B18]\]. A previous study reported that 20%-60% of patients with gout and hyperuricemia developed renal impairment that was accompanied by histological damage of glomerulosclerosis, interstitial fibrosis, and arteriosclerosis\[[@B19]\]. Again, elevated sUA levels have been reported to predict the development of renal insufficiency in individuals with normal renal function\[[@B20]\].

Recent data underscoring the growing problem of gout and its associated comorbid conditions have called for the need for more research of its impact on major outcomes. Evidence from large data sets has reported uric acid levels to be associated with the risk of end-stage renal disease (ESRD)\[[@B21]-[@B23]\]. Clinical evidence from randomized clinical trials is now emerging showing that allopurinol may slow the progression of CKD\[[@B24]\]. In a study using continued allopurinol treatment as a proxy for control, long-term treatment was suggestive of slowing the rate of kidney disease progression and reducing CV risk\[[@B25]\]. Thus, the present study assessed the impact of allopurinol non-adherence as a proxy for uncontrolled disease\[[@B25]\] on primary prevention of ESRD among patients newly treated with allopurinol for gout treatment. The objective was to assess the impact of gout disease control on the risk of ESRD among gout patients newly treated with allopurinol in a cohort of patients who initiated antihypertensive agents for essential hypertension.

MATERIALS AND METHODS
=====================

Data sources
------------

This population-based study utilized the Régie de l'assurance maladie du Québec (RAMQ) and MedEcho databases, both of which are components of public health care insurance program management for Quebec, Canada. Specific types of health data comprise the RAMQ databases: (1) a demographic information file of all registrants, containing gender, age, postal code, and, if applicable, year of death; and (2) a medical services file, consisting of all inpatient/ambulatory medical services claims, that includes procedure/diagnostic code data, *i.e*., date, type, and site (office, emergency room, hospital). Diagnostic coding was performed according to the International Classification of Disease, Ninth Revision (*ICD-9*) and, from 2006 onward, *ICD-10*.

The Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures enclose and define the procedure codes. All drugs prescribed to patients who take RAMQ-insured medications are contained in the pharmaceutical file. The pharmaceutical file includes the name and dose of the drug, its quantity, date of treatment dispensation, and the quantity of days dispensed, as indicated by the pharmacist. Lastly, the MedEcho database file contains data on acute care hospitalizations, (*e.g*., admission date, length of stay, and primary/secondary diagnoses). Each of the database files also provided a unique identifier (individual health insurance number).

The first 2 RAMQ datasets contain information on all of those with provincial public health insurance plan coverage, comprising the total Quebec population. Prescription claims dataset (pharmaceutical file) data are from provincial public prescription drug insurance plan beneficiaries, representing approximately 43% of Quebec residents between the ages of 45 and 64, and about 94% of those aged ≥ 65 years. This dataset provides an accurate measure of identifying drugs that are prescribed to patients and is a validated research tool utilized in pharmacoepidemiologic studies. RAMQ database medical services claims have been also used as part of validity studies\[[@B26]-[@B30]\].

Cohort definition
-----------------

Subjects identified were aged 45 to 85 and newly treated with either angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium channel blockers, diuretics, or a combination between January 1, 1999 and June 30, 2007; these subjects were also required to have an essential hypertension diagnosis (*ICD-9* code: 401 and *ICD-10* code: I10) for 2 years prior to the cohort entry date. The study cohort included 222582 individuals.

The exclusion criteria were as follows: (1) patients with hematologic cancer *ICD-9* code 200-208 or *ICD-10* code C77-C96 in the 5-year period prior to the cohort entry date*;* (2) other disorders of purine and pyrimidine metabolism *ICD-9* code 277.2 or *ICD-10* code E79.0, E79.1, E79.8, E79.9 in the 5-year period prior to the cohort entry date; (3) patients with tumor lysis syndrome *ICD-9* code 277.88 or *ICD-10* E88.3, E88.8, E88.9 in the 5-year period prior to the cohort entry date; (4) patients with familial Mediterranean fever *ICD-9* code 277.31 or *ICD-10* code E85.0 in the 5-year period prior to the cohort entry date; (5) patients with hemodialysis or peritoneal dialysis for more than 3 consecutive months in the 5-year period prior to the cohort entry date; (6) patients with autoimmune/congenital kidney diseases, as these conditions are highly associated with kidney diseases and, as a result, are also highly predictive of ESRD; (7) patients with kidney transplantation; and (8) patients with expected CKD of stage 4 and 5 using *ICD-9* or *ICD-10* with the presence of drug markers (in the 2 years prior to cohort entry date): Calcium carbonate ≥ 1200 mg/d or calcitriol (≥ 0.25 μg/d or ≥ 1.75 μg/wk or ≥ 7.5 μg/30 d) or doxercalciférol (≥ 2.5 μg/d or ≥ 17.5 μg/wk or ≥ 75 μg/30 d) or alfacalcidol ( ≥ 0.25 μg/d or ≥ 1.75 μg/wk or ≥ 7.5 μg/30 d).

We defined the patients as newly treated with allopurinol if they had not taken any allopurinol in 1 year during the follow-up. The date of the cohort entry is defined by the date of the first claim of allopurinol. In order to be eligible, patients needed to also have had a diagnosis of gout, defined as meeting all of the following criteria: (1) having a diagnosis of gout defined by *ICD-9* code 712.0 *(Gout arthritis) or ICD-9* code 274 (*Gout*) or *ICD-10* code M10.0 *(Idiopathic gout)* or *ICD-10* M10.9 (*Non-specify gout*) during the follow-up period; and (2) users of at least 2 claims of colchicine during the follow-up period (meaning any time during the follow-up prior and post inclusion in the cohort).

The study cohort included all new users of allopurinol who were followed from the date of first allopurinol claim issuance until the onset of ESRD or study period end (*i.e*., June 30, 2008). Individuals were censored when they lost RAMQ drug insurance coverage or died during follow-up. Subjects were followed for a period of 1 year to 9.5 years.

Nested case-control study
-------------------------

We conducted a nested case-control study to estimate rate ratios (RR) of ESRD associated with adherence to allopurinol for gout treatment. The definition of ESRD (case) comprised a composite endpoint that represented patients with a medical procedure lasting ≥ 3 mo' for peritoneal dialysis, hemodialysis, or renal transplantation. The date of ESRD was defined as the index date. All cases were identified and up to 15 controls were randomly selected from the cohort based on the risk set of each case using density sampling. Sampling for each control was selected in proportion to time contribution to the person-time at risk in the source population (*i.e*., the whole cohort), giving an unbiased estimate of the RR. A hallmark of the risk set is that a cohort member who serves as control at one point in time may later become a case, and the same cohort member may be selected as a control for more than 1 case. Cases and controls were matched for age, sex, and entry into the cohort.

Ascertainment of ESRD
---------------------

The primary outcome was ESRD described by the (case) composite endpoint case definition above. All patients were followed up to study end or primary outcome.

Exposure to allopurinol during the follow-up period
---------------------------------------------------

The definition of allopurinol adherence was described as the degree at which patients use allopurinol as prescribed. Adherence estimation was determined *via* "medication possession ratio" (MPR), which was calculated as the total number of days' supply of medication dispensed divided by follow-up length. Evaluation of patient adherence was conducted from initiation of follow-up to index date (date of ESRD) or to time of non-cases' selection. MPR was dichotomized, with an MPR threshold set to \< 80% in order to identify those who were non-adherent, which is aligned to the medical literature. We also used categorical exposure. In many databases, serum urate is not captured and adherence to urate-lowering therapy may be a proxy for disease control\[[@B31],[@B32]\].

Variables for assessing risk factors for gout and associated co-morbidities
---------------------------------------------------------------------------

Social assistance status and gender at the time of cohort entry was established using RAMQ database beneficiary file data. Risk factors for gout and associated comorbidities were considered using drug markers or *ICD-9*/*ICD-10*. Associated comorbidities were ischemic heart disease, heart failure, cardiac dysrhythmias, dyslipidemia, diabetes, CKD at grades 1 to 3, acute renal failure, cerebrovascular disease, peripheral vascular disease, pulmonary disease (chronic obstructive pulmonary disease or asthma), dementia, rheumatic disease, and gastrointestinal disease. Diagnosis and medical procedures were identified in the 5 years preceding cohort entry, while pharmacological treatment was identified in the 2 years preceding cohort entry date. Indirect measurement of hypertension severity was established by the number of antihypertensive medications (1, 2, ≥ 3) during the year prior to the index date.

Statistical analysis
--------------------

Comparison of characteristics of controlled and uncontrolled patients was calculated using *t*-test for continuous variables and *χ*^2^ test for categorical variables. Through multivariate analysis, a conditional logistic regression model was constructed to evaluate the association between allopurinol adherence and ESRD. When studying a time-dependent exposure, as adherence to allopurinol in our study, an additional level of complexity is introduced based upon the need to account for a time-dependent exposure; this can be achieved *via* a cohort analysis using Cox regression that includes time-dependent covariates. Alternatively, the use of a nested case-control approach is appropriate, providing exposure and covariate information for controls and reflecting values corresponding to the selection time of their respective case. When studying time-dependent exposures, nested case-control analyses can yield similar results to that of Cox regression on the full cohort; the advantage being that there is superior computational efficiency with conditional logistic regression (given that only a sample of all possible controls are included in each case's risk set). Aside from computational efficiency, the use of nested case-control studies offer additional advantages, including the possibility of matching controls to cases on the basis of possible fixed or time-dependent confounding covariates for which estimation of effect is not of interest.

To further weigh the strength of the findings, sensitivity analyses were performed to validate our approach. The validity of the approach was done by analyzing 2 drug variables (*i.e*., benzodiazepines, proton pump inhibitors) and examining varying usage patterns (adherence level \< 80% and ≥ 80%). The goal was to determine whether adherence to non-renal-protective drugs was also associated with a reduced ESRD risk. By considering the potential influence of adherence to different classes of drugs, we were able to ensure that any impact on ESRD was due to allopurinol non-adherence, and not the potential influence from simultaneously discontinuing several other medications.

Unselected multivariable models were constructed to maximize adjustment for co-variables. Based on the number of cases, we included only CKD and severity of hypertension to obtain the adjusted estimators. RRs and 95% confidence intervals (CIs) were calculated for each independent variable in the multivariable models. Residuals from regression models were assessed for assumptions violations of multicollinearity or deviance. A precision threshold of 5% was utilized for all analyses and was executed utilizing SAS version 9.3 (SAS Institute, Cary, North Carolina, United States).

RESULTS
=======

Patient characteristics
-----------------------

After inclusion/exclusion criteria were applied (Figure [1](#F1){ref-type="fig"}), the resulting cohort at entry comprised 2752 patients with a mean age of 67 years; more than 82% of them were male, 23% of advanced age (\> 75 years), close to 50% had at least 1 CVD, 33.5% had dyslipidemia, 20.7% had diabetes, 12.7% had CKD, 21.1% were thiazides users, 34.3% were low acetylsalicylic acid users, and 42.8% were nonsteroidal anti-inflammatory drug (NSAID) users (Table [1](#T1){ref-type="table"}).

###### 

Demographic and clinical characteristics of new users of allopurinol treatment in a cohort of treated for hypertension from 1999 to 2007

  ------------------------------------------------------------------------ -------------
  All patients (*n*)                                                       2752
  Mean (SD) age, yr[1](#T1FN1){ref-type="table-fn"}                        67 (9)
  Risk factors for gout, % (*n*)                                           
  Advanced age (\> 75 yr)[1](#T1FN1){ref-type="table-fn"}                  23.0 (634)
  Male[1](#T1FN1){ref-type="table-fn"}                                     82.8 (2278)
  Obesity[2](#T1FN2){ref-type="table-fn"}                                  6.5 (179)
  Drug use, % (*n*)                                                        
  Thiazides[3](#T1FN3){ref-type="table-fn"}                                21.1 (581)
  Low dose acetylsalicylic acid[3](#T1FN3){ref-type="table-fn"}            34.3 (945)
  Niacin[3](#T1FN3){ref-type="table-fn"}                                   0.4 (11)
  Alcoholic diagnosis[3](#T1FN3){ref-type="table-fn"}                      1.3 (35)
  Thyroid problems[3](#T1FN3){ref-type="table-fn"}                         12.9 (356)
  Associated comorbidities, % (*n*)                                        
  Ischemic heart disease[2](#T1FN2){ref-type="table-fn"}                   30.9 (849)
  Heart failure[2](#T1FN2){ref-type="table-fn"}                            10.5 (288)
  Cardiac dysrhythmias[2](#T1FN2){ref-type="table-fn"}                     12.5 (343)
  Atrial fibrillation and flutter[2](#T1FN2){ref-type="table-fn"}          8.1 (224)
  Peripheral vascular disease[2](#T1FN2){ref-type="table-fn"}              11.7 (321)
  Cerebrovascular disease[2](#T1FN2){ref-type="table-fn"}                  12.0 (330)
  Dyslipidemia[2](#T1FN2){ref-type="table-fn"}                             33.5 (921)
  Diabetes[2](#T1FN2){ref-type="table-fn"}                                 20.7 (569)
  Chronic kidney disease at grade 1 to 3[4](#T1FN4){ref-type="table-fn"}   12.7 (350)
  Acute renal failure[2](#T1FN2){ref-type="table-fn"}                      4.3 (117)
  Pulmonary disease (COPD/asthma)[2](#T1FN2){ref-type="table-fn"}          30.8 (847)
  Dementia[2](#T1FN2){ref-type="table-fn"}                                 2.7 (73)
  Rheumatic disease[2](#T1FN2){ref-type="table-fn"}                        6.3 (174)
  Gastrointestinal disease[2](#T1FN2){ref-type="table-fn"}                 7.9 (218)
  Drug use for gout treatment, % (*n*)                                     
  NSAIDs[3](#T1FN3){ref-type="table-fn"}                                   42.8 (1178)
  Colchicine[3](#T1FN3){ref-type="table-fn"}                               29.3 (806)
  Intra-articular corticosteroids[3](#T1FN3){ref-type="table-fn"}          5.9 (163)
  Oral corticosteroids[3](#T1FN3){ref-type="table-fn"}                     2.4 (65)
  Narcotics[3](#T1FN3){ref-type="table-fn"}                                12.8 (353)
  ------------------------------------------------------------------------ -------------

At treatment initiation;

*ICD-9* or *ICD-10* identified in the 5 years preceding cohort entry;

Pharmacologic treatment identified in the 2 years preceding cohort entry;

Chronic kidney disease at grade 1 to 3 defined as having *ICD-9* or *ICD-10* with the absence of medication for phosphate binding or for hyperparathyroidism control. COPD: Chronic obstructive pulmonary disease; NSAIDs: Nonsteroidal anti-inflammatory drugs.

![Flowchart of inclusion and exclusion criteria: Exclusion criteria were applied in the 5 years preceding the cohort entry date for diagnoses and medical procedures and 2 years prior to the cohort entry date for medication. RAMQ: Régie de l'assurance maladie du Québec.](WJN-6-132-g001){#F1}

Table [2](#T2){ref-type="table"} provides a listing of patient demographic and clinical characteristics at cohort entry, stratified by adherence level within the cohort. No major clinically significant difference was observed between the groups. The median time of follow-up was 3.9 years. Over the time of follow-up, 22 ESRD cases o (0.80%, or 0.2 per 100 person-years) were identified. Over the course of follow-up for the entire cohort, the death rate was 6.7% (183 deaths, or 1.58 per 100 person-years). The allopurinol exposure at the baseline level and during follow-up is provided in Table [3](#T3){ref-type="table"}.

###### 

Demographic and clinical characteristics of adherent and non-adherent patients to allopurinol treatment in a cohort of newly treated antihypertensive patients from 1999 to 2007

  **Variables**                                                            **Adherent to allopurinol**   **Non-adherent to allopurinol**   ***P*-value**
  ------------------------------------------------------------------------ ----------------------------- --------------------------------- ---------------
  All patients (*n*)                                                       1392                          1360                              
  Mean (SD) age (yr)[1](#T2FN1){ref-type="table-fn"}                       67 (9)                        67 (9)                            0.4457
  Risk factors for gout, % (*n*)                                                                                                           
  Advanced age (\> 75 yr)[1](#T2FN1){ref-type="table-fn"}                  22.2 (309)                    23.9 (325)                        0.2900
  Male[1](#T2FN1){ref-type="table-fn"}                                     84.2 (1172)                   81.3 (1106)                       0.0367
  Obesity[2](#T2FN2){ref-type="table-fn"}                                  6.4 (89)                      6.6 (90)                          0.8117
  Drug use                                                                                                                                 
  Thiazides[3](#T2FN3){ref-type="table-fn"}                                20.0 (278)                    22.3 (303)                        0.1380
  Low dose acetylsalicylic acid[3](#T2FN3){ref-type="table-fn"}            35.8 (499)                    32.8 (446)                        0.0917
  Niacin[3](#T2FN3){ref-type="table-fn"}                                   0.4 (5)                       0.4 (6)                           0.7333
  Alcoholic diagnosis[2](#T2FN2){ref-type="table-fn"}                      1.2 (16)                      1.4 (19)                          0.5622
  Thyroid problems[2](#T2FN2){ref-type="table-fn"}                         13.1 (182)                    12.8 (174)                        0.8264
  Associated comorbidities, % (*n*)                                                                                                        
  Ischemic heart disease[2](#T2FN2){ref-type="table-fn"}                   31.3 (435)                    30.4 (414)                        0.6460
  Chronic heart failure[2](#T2FN2){ref-type="table-fn"}                    10.7 (149)                    10.2 (139)                        0.6787
  Cardiac dysrhythmias[2](#T2FN2){ref-type="table-fn"}                     11.5 (160)                    13.5 (183)                        0.1193
  Atrial fibrillation and flutter[2](#T2FN2){ref-type="table-fn"}          7.5 (104)                     8.8 (120)                         0.1946
  Peripheral vascular disease[2](#T2FN2){ref-type="table-fn"}              12.1 (168)                    11.3 (153)                        0.5034
  Cerebrovascular disease[2](#T2FN2){ref-type="table-fn"}                  12.3 (172)                    11.6 (158)                        0.5509
  Dyslipidemia[2](#T2FN2){ref-type="table-fn"}                             35.0 (487)                    31.9 (434)                        0.0875
  Diabetes[2](#T2FN2){ref-type="table-fn"}                                 21.1 (294)                    20.2 (275)                        0.5599
  Chronic kidney disease at grade 1 to 3[4](#T2FN4){ref-type="table-fn"}   12.7 (177)                    12.7 (173)                        0.9968
  Acute renal failure[2](#T2FN2){ref-type="table-fn"}                      4.3 (60)                      4.2 (57)                          0.8769
  Pulmonary disease (COPD/asthma)[2](#T2FN2){ref-type="table-fn"}          31.4 (437)                    30.1 (410)                        0.4787
  Dementia[2](#T2FN2){ref-type="table-fn"}                                 2.9 (40)                      2.4 (33)                          0.4656
  Rheumatic disease[2](#T2FN2){ref-type="table-fn"}                        5.0 (69)                      7.7 (105)                         0.0029
  Gastrointestinal disease[2](#T2FN2){ref-type="table-fn"}                 7.5 (105)                     8.3 (113)                         0.4571
  Drug use for gout treatment[3](#T2FN3){ref-type="table-fn"}, % (*n*)                                                                     
  NSAIDs[3](#T2FN3){ref-type="table-fn"}                                   37.8 (526)                    47.9 (652)                        \< 0.0001
  Colchicine[3](#T2FN3){ref-type="table-fn"}                               26.9 (374)                    31.8 (432)                        0.0048
  Intra-articular corticosteroids[3](#T2FN3){ref-type="table-fn"}          6.4 (89)                      5.4 (74)                          0.2899
  Oral corticosteroids[3](#T2FN3){ref-type="table-fn"}                     1.9 (27)                      2.8 (38)                          0.1400
  Narcotics[3](#T2FN3){ref-type="table-fn"}                                12.9 (179)                    12.8 (174)                        0.9593

At treatment initiation;

*ICD-9* or *ICD-10* identified in the 5 years preceding cohort entry;

Pharmacologic treatment identified in the 2 years preceding cohort entry;

Chronic kidney disease at grade 1 to 3 defined as having *ICD-9* or *ICD-10* with the absence of medication for phosphate binding or for hyperparathyroidism control. COPD: Chronic obstructive pulmonary disease; NSAIDs: Nonsteroidal anti-inflammatory drugs.

###### 

Exposure to allopurinol

                                                                           **Baseline**     **During follow-up**
  ------------------------------------------------------------------------ ---------------- ----------------------
  Patients (*n*)                                                           2752             2570
  Allopurinol                                                                               
  Mean dose used during the period (± SD)                                  210.9 (± 97.5)   243.3 (± 128.2)
  Proportion of patients taking \< 300 mg (%)                              64.7 (1782)      53.5 (1374)
  Proportion of patients taking 300 mg (%)                                 33.5 (921)       40.8 (1049)
  Proportion of patients taking \> 300 mg (%)                              1.8 (49)         5.7 (147)
  Febuxostat                                                                                
  Proportion of patients who received at least 1 claim of febuxostat (%)   0 (0)            0 (0)
  Mean dose used during the period (± SD)                                  NA               NA

NA: Not applicable.

As shown in Table [4](#T4){ref-type="table"}, among the 22 cases (matched for age, sex, and time period), CVD and associated risk factors, as well as other comorbidities were higher among controls compared with cases. In contrast, CKD at a grade lower than 4, acute renal failure, and severity of hypertension were higher among cases than controls.

###### 

Characteristics of patients with end-stage renal disease and their matched controls

                                                                             **Cases occurring in the follow-up and their controls**   
  -------------------------------------------------------------------------- --------------------------------------------------------- --------------
  Characteristics, % (*n*) unless otherwise noted                                                                                      
  Allopurinol adherence ≥ 80%                                                31.8 (7)                                                  57.1 (182)
  Age (mean, continuous)[1](#T4FN1){ref-type="table-fn"}                     74.2 (60-78)                                              74.8 (60-78)
  Older than 75 yr[1](#T4FN1){ref-type="table-fn"}                           36.4 (8)                                                  38.6 (123)
  Ischemic heart disease[2](#T4FN2){ref-type="table-fn"}                     18.2 (4)                                                  24.8 (79)
  Heart failure[2](#T4FN2){ref-type="table-fn"}                              9.1 (2)                                                   8.5 (27)
  Cardiac dysrhythmias[2](#T4FN2){ref-type="table-fn"}                       0 (0)                                                     8.2 (26)
  Atrial fibrillation[2](#T4FN2){ref-type="table-fn"}                        0 (0)                                                     4.7 (15)
  Peripheral arterial disease[2](#T4FN2){ref-type="table-fn"}                9.1 (2)                                                   12.5 (40)
  Cerebrovascular disease[2](#T4FN2){ref-type="table-fn"}                    18.2 (4)                                                  14.7 (47)
  Dyslipidemia[2](#T4FN2){ref-type="table-fn"}                               13.6 (3)                                                  29.8 (95)
  Diabetes[2](#T4FN2){ref-type="table-fn"}                                   18.2 (4)                                                  19.1 (258)
  Chronic kidney disease with grade 1 to 3[3](#T4FN3){ref-type="table-fn"}   54.6 (12)                                                 12.9 (41)
  Acute renal failure[2](#T4FN2){ref-type="table-fn"}                        9.1 (2)                                                   3.1 (10)
  Pulmonary disease (COPD/asthma)[2](#T4FN2){ref-type="table-fn"}            22.7 (5)                                                  37.6 (120)
  Dementia[2](#T4FN2){ref-type="table-fn"}                                   4.6 (1)                                                   1.6 (5)
  Rheumatic disease[2](#T4FN2){ref-type="table-fn"}                          4.6 (1)                                                   5.6 (18)
  Gastrointestinal disease[2](#T4FN2){ref-type="table-fn"}                   4.6 (1)                                                   11.3 (36)
  Severity of hypertension (1-yr prior to ESRD)                                                                                        
  No use of antihypertensive agent                                           4.6 (1)                                                   8.8 (28)
  Monotherapy                                                                36.4 (8)                                                  43.0 (137)
  2 antihypertensive agents                                                  36.4 (8)                                                  35.1 (112)
  ≥ 3 antihypertensive agents                                                22.7 (5)                                                  13.2 (42)

At treatment initiation;

*ICD-9* or *ICD-10* identified in the 5 years preceding cohort entry;

Chronic kidney disease at grade 1 to 3 defined as having *ICD-9* or *ICD-10* with the absence of medication for phosphate binding or for hyperparathyroidism control. COPD: Chronic obstructive pulmonary disease; ESRD: End-stage renal disease.

Impact of allopurinol adherence level on ESRD
---------------------------------------------

The incidence rate of ESRD for high adherence subjects compared with lower adherence is shown in Figure [2](#F2){ref-type="fig"}. The mean (SD) adherence level to allopurinol was 65.7% (32.6%). The adjusted RR of ESRD was significantly lower in the high adherence group compared with the lower adherence group (RR = 0.35; 95%CI: 0.13-0.91) (Table [5](#T5){ref-type="table"}). We identified 22 cases with ESRD during follow-up. High adherence (≥ 80%) to allopurinol therapy compared with lower adherence (\< 80%) was associated with a reduction of ESRD. Major risk factors for ESRD were CKD at stage 1 to 3 (RR = 8.00; 95%CI: 3.16-22.3) and a trend for severity of hypertension (RR = 1.19; 95%CI: 0.38-3.74). Adjusted variables were limited in number, given the low number of cases, and subgroup analyses were unable to be conducted.

![Nonadjusted cumulative incidence rate of end-stage renal disease among high adherence level compared with the low level of adherence of allopurinol over time in years. ESRD: End-stage renal disease.](WJN-6-132-g002){#F2}

###### 

Rate ratio of end-stage renal disease

                                                                           **Rate ratio[(95%CI)]{.smallcaps}**   
  ------------------------------------------------------------------------ ------------------------------------- -------------------
  Allopurinol adherence level                                                                                    
  \< 80%                                                                   Reference                             Reference
  ≥ 80%                                                                    0.35 (0.14-0.89)                      0.35 (0.13-0.91)
  Chronic kidney disease at grade 1 to 3[1](#T5FN1){ref-type="table-fn"}   8.06 (3.28-19.77)                     8.00 (3.16-20.25)
  Severity of hypertension (1 yr prior to ESRD)                                                                  
  \< 3 antihypertensive agents                                             Reference                             Reference
  ≥ 3 antihypertensive agents                                              1.94 (0.68-5.51)                      1.19 (0.38-3.74)

Chronic kidney disease at grade 1 to 3 defined as having *ICD-9* or *ICD-10* with the absence of medication for phosphate binding or for hyperparathyroidism control. Chronic kidney disease and severity of hypertension were the variables used to obtain the adjusted estimators. CI: Confidence interval; ESRD: End-stage renal disease.

Validation of methodological approach
-------------------------------------

An adherence rate of \> 80% to proton pump inhibitors (RR = 0.90; 95%CI: 0.20-4.01) or benzodiazepines (RR = 1.24; 95%CI: 0.35-4.39) did not impact onset of ESRD. High allopurinol adherence specifically was associated with reduction of ESRD; however, with non-renal protective drugs, this effect was not present.

DISCUSSION
==========

This study shows that allopurinol treatment adherence of ≥ 80% as a proxy for gout control in this newly-treated population is associated with a significant 65% decrease in the risk of ESRD onset. The association seems to take more than 3 years of exposure, suggesting that allopurinol efficacy in preventing ESRD may need many years before manifesting. This aligns with the medical literature and supports the assertion that the development of ESRD occurs over an extended time period\[[@B33]\].

Our results are in accordance with recent publications, which suggest that lowering sUA levels may slow progression of renal disease. Siu et al\[[@B34]\] reported that the treatment of asymptomatic hyperuricemia in patients with mild renal disease (CKD stage 3) resulted in delayed disease progression. Likewise, Kanbay et al\[[@B35]\] reported that treatment with asymptomatic hyperuricemia improved renal function.

The present study results indicate that CKD at a lower stage and the severity of hypertension disease are associated with increased risk of ESRD onset\[[@B36]-[@B41]\]. The most difficult aspect of assessing the impact of allopurinol and disease control in the development or progression of CKD is the number of confounders. Here, we were limited in the number of adjusted variables given the low number of cases, and we were unable to conduct a subgroup analysis. In addition, we were limited to control for severity of hypertension. The concept of an ideal blood pressure target for patients with kidney disease is highly debated\[[@B42]\]. Two critical factors arise: Follow-up time and proteinuria; both factors appear to be important in influencing blood pressure effects in nephroprotection. Our study design does not allow for the verification of the proteinuria hypotheses; however, the importance of time can be agreed upon, as a more significant effect of good allopurinol adherence over more than 3 years was observed. We were also unable to discern what the targeted or achieved blood pressure levels were for our cohort. If lower blood pressure does not convey a lower ESRD risk (a controversial subject), and if our chronic renal failure patients and controls had in fact ended up with lower blood pressures (\< 130/80), then this may decrease the strength of the observed association.

The study design took the potential for some methodology-based limitations into consideration. In order to avoid selection bias, only incident allopurinol users were included. Nevertheless, additional limitations potentially remain. First, to control for certain risk factors involved in CKD development, we included any variables that were relevant within the regression model. Since those with higher amounts of comorbidities have a higher likelihood for ESRD, we adjusted for limited risk factors given the number of observed cases. Regardless, one cannot exclude residual confounding due to inaccurate/incomplete measurement of covariates or unmeasured confounders. As an example, patients not adhering to treatment could likely have additional factors contributing to worse outcomes, such as lower socioeconomic status, adverse health behaviors, and depression\[[@B43]\]. Nonetheless, we were able to adjust for these factors.

Our sensitivity analyses regarding the differential class effects of drug adherence on ESRD suggest that adherence-related benefits are associated with medication that lowered sUA levels. The benefit on reduction of ESRD in our study was seen specifically with better adherence to medication that lowered sUA levels, but not with other types of medications such as proton pump inhibitors or benzodiazepines. Still, the possibility remained for "healthy user bias"\[[@B44],[@B45]\]. This term refers to a population of patients that exhibit good adherence to medication as part of an overall healthy lifestyle, and therefore, have less comorbidities and, as a result, exhibit decreased risk of disease development overall. Of note, recent literature discussing differential drug adherence class effects on long-term survival proposed that the associated benefits related to pharmacotherapeutic adherence are mediated more so by the effects of the drugs rather than by healthy adherence behaviors\[[@B46]\]. Another possibility could have been reverse causality. Each patient's glomerular filtration rate were unknown based on the information available from the administrative databases utilized in this observational study; however, renal function decline was likely to be gradual over the course of a few years, while adherence remained quite constant after the first year and until the index date in both cases and controls. Hence, it is not believed that decreasing renal function resulted in patients becoming more compliant to medication.

Additionally, the evidence surrounding the safety and efficacy of allopurinol among patients with CKD presents an inconsistency of results\[[@B47]\]. We should be aware of the potential risk of allopurinol use among those patients, and we need to titrate according to target sUA level or switch to febuxostat\[[@B48]\]. In our study, we do not suspect that allopurinol non-adherence was related to CKD progression; this is because febuxostat was available to the physician, but the opportunity to switch the patient was not carried out.

Characteristics potentially influencing a doctor's medication choice, such as unmeasured comorbidities and missing sUA level/blood pressure control data, were not able to be controlled for in our analysis; this potentially could result in residual confounding effects. In addition, adjusting for clinical severity, *e.g*., precise glomerular filtration rate, CKD etiology, proteinuria, is not allowable with the use of databases. However, these conditions *per se* are not traditionally associated with better adherence. Also, due to diagnostic coding errors, it is possible that history of renal disease may not have been identified in certain individuals. The probability of this occurring, however, would have been low, as for all individuals, relevant medical/drug information was accessible for all individuals for a several-year period prior to cohort entry. For instance, 12 of the 22 ESRD events had previous CKD (classified as grade 1 to 3); 2 had a history of acute renal failure, and the 8 remaining cases developed CKD during follow-up as the cause of ERSD. Patients with previously diagnosed gout (as opposed to those with newly diagnosed gout) also may have greater motivation to take their medication based on prior gout attack experiences\[[@B49]\]. Patients with previously diagnosed gout may be at higher risk, but this could not be adjusted because of the low number of cases. NSAID use may also be a confounder since its use may cause progression among patients who have pre-existing kidney disease\[[@B50]\]. After adjusting for age, gender, and comorbidities, high cumulative NSAID use was associated with a 26% risk of a rapid decline in estimated glomerular filtration rate relative to those who did not use NSAIDs (OR = 1.26, 95%CI: 1.04--1.53). For instance, in our study, we noticed a difference in NSAID users between adherent (37.8%) and non-adherent (47.9%) participants; however, we could not adjust because of the low number of cases. Nevertheless, we do not expect that this difference could have a major impact, given that there was no difference among patients with CKD at grade 1 to 3 for the low and high allopurinol adherence levels.

Finally, prescription refill patterns were used to assess exposure; therefore, whether the dispensed medication was actually taken by the patient cannot be ascertained. Nevertheless, evidence suggests a good correlation between cumulative drug exposure, pharmacy dispensing records, and gaps in medication supply\[[@B51]\]. Furthermore, no information with respect to potential adverse drug effects was available within the data, which could potentially explain early medication discontinuation. Available evidence has shown that adverse drug effects generally occur in the earlier, rather than later, phases of treatment; therefore, it is unlikely to significantly account for non-adherence of preventive therapy\[[@B52]\].

To summarize, this Canadian population-based study showed an association with significant benefit between good allopurinol adherence, as a proxy for disease control, and ESRD onset, but further research should be conducted to confirm this potential associated risk.

A key factor to determining success with various treatment approaches is improved adherence to pharmacotherapy. As a result, greater awareness should be taken accordingly, as improved patient outcomes can result. Assessing medication adherence should be a routine part of clinical practice. Devising strategies to optimize long-term allopurinol adherence, as well as other measures of adequate disease control, must be encouraged in order to lower or, at a minimum, delay the occurrence of ESRD in patients with gout.
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Background
----------

Gout is characterized by elevated serum uric acid (sUA) levels and is commonly treated with urate-lowering treatment allopurinol; however, allopurinol adherence is suboptimal and therefore a therapeutic challenge in gout. Some evidence from large data sets has reported sUA to be associated with the risk of end-stage renal disease (ESRD), and hyperuricemia in general is common in chronic kidney disease (CKD).

Research frontiers
------------------

Several observational studies have been either inconclusive or conflicting as to whether elevated sUA is an independent risk factor for the development and progression of CKD. The pathogenic role of sUA in the onset and progression of CKD, and the relationship of sUA management in this context, remains largely unanswered.

Innovations and breakthroughs
-----------------------------

This study examines a large cohort of over 220000 individuals followed for up to 9 years and utilizes long-term real-world evidence to examine the impact of gout control on the onset of ESRD.

Applications
------------

This study found a potential association with significant benefit between good adherence to allopurinol and ESRD onset. Optimizing long-term allopurinol adherence and other measures of disease control must be encouraged in order to lower or, as a minimum, delay the occurrence of ESRD in patients with gout.
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In their manuscript Perreault et al studied an important topic; the possible role of allopurinol non-adherence in the development of end-stage renal disease in gout patients. The authors used very sophisticated statistics in their case control study on a high patient population.
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